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Abstract
Background: Lassa fever is a viral hemorrhagic fever endemic in West Africa. However, none of the hospitals in the endemic
areas of Nigeria has the capacity to perform Lassa virus diagnostics. Case identification and management solely relies on
non-specific clinical criteria. The Irrua Specialist Teaching Hospital (ISTH) in the central senatorial district of Edo State
struggled with this challenge for many years.
Methodology/Principal Findings: A laboratory for molecular diagnosis of Lassa fever, complying with basic standards of
diagnostic PCR facilities, was established at ISTH in 2008. During 2009 through 2010, samples of 1,650 suspected cases were
processed, of which 198 (12%) tested positive by Lassa virus RT-PCR. No remarkable demographic differences were
observed between PCR-positive and negative patients. The case fatality rate for Lassa fever was 31%. Nearly two thirds of
confirmed cases attended the emergency departments of ISTH. The time window for therapeutic intervention was
extremely short, as 50% of the fatal cases died within 2 days of hospitalization—often before ribavirin treatment could be
commenced. Fatal Lassa fever cases were older (p=0.005), had lower body temperature (p,0.0001), and had higher
creatinine (p,0.0001) and blood urea levels (p,0.0001) than survivors. Lassa fever incidence in the hospital followed a
seasonal pattern with a peak between November and March. Lassa virus sequences obtained from the patients originating
from Edo State formed—within lineage II—a separate clade that could be further subdivided into three clusters.
Conclusions/Significance: Lassa fever case management was improved at a tertiary health institution in Nigeria through
establishment of a laboratory for routine diagnostics of Lassa virus. Data collected in two years of operation demonstrate
that Lassa fever is a serious public health problem in Edo State and reveal new insights into the disease in hospitalized
patients.
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Lassa fever is a viral hemorrhagic fever that was first described
in 1969 in the town of Lassa in the North-East of Nigeria [1]. It is
endemic in the West African countries of Sierra Leone, Guinea,
Liberia, and Nigeria ([2,3] and references therein). Cases imported
to Europe indicate that Lassa fever also occurs in Co ˆte d’Ivoire
and Mali [4,5]. The causative agent is Lassa virus, an RNA virus
of the family Arenaviridae. Its natural host is the rodent Mastomys
natalensis [6,7], which lives in close contact to humans. Mastomys
shed the virus in urine [8] and contamination of human food is a
likely mode of transmission. The virus may be further transmitted
from human to human, giving rise to mainly nosocomial
epidemics with case fatality rates (CFR) of up to 65% [9–12].
However, most of the Lassa virus infections in the communities are
probably mild [13].
Clinically, Lassa fever is extremely difficult to distinguish from
other febrile illnesses seen in West African hospitals, at least in the
initial phase [14,15]. Gastrointestinal symptoms, pharyngitis, and
cough are frequent signs. Late complications include pleural and
pericardial effusions, facial edema, bleeding, convulsion, and
coma. In the terminal stage patients often go into shock, although
bleeding itself is usually not of a magnitude to produce shock
[10,14–22]. The only drug with a proven therapeutic effect in
humans is the nucleoside analogue ribavirin. Drug efficacy
decreases if treatment is commenced at day 7 or later [23],
making early diagnostics critical for survival.
Lassa virus can be detected in blood at an early stage of illness.
Death occurs about two weeks after onset of illness with fatal cases
showing higher levels of viremia than those who survive. In
survivors, virus is cleared from circulation about three weeks after
onset of symptoms [24–26]. IgM and IgG antibodies are
detectable only in a fraction of patients during the first days of
illness, and patients with fatal Lassa fever may not develop
antibodies at all [24,26,27]. Therefore, RT-PCR is a valuable tool
for rapid and early diagnosis of Lassa fever [24,25,28,29].
So far, diagnostic testing of samples from Lassa fever patients
has been performed almost exclusively outside of Africa. Only the
laboratory at the hospital in Kenema, Sierra Leone, which has
become operational since 2004 (after civil war forced its closure in
1993), is able to perform Lassa fever testing for patients [30]. In
Nigeria, the situation improved with the implementation of Lassa
virus PCR testing at a research laboratory of the University of
Lagos, which facilitated retrospective laboratory confirmation of
Lassa fever cases in various parts of the country [31,32]. However,
none of the hospitals in the endemic areas of Nigeria has the
capacity to perform Lassa virus tests. Case management is thus
mainly based on non-specific clinical criteria [14,15] and in the
worst cases, health care workers became infected while they
treated patients without knowing they had Lassa fever [32].
The Irrua Specialist Teaching Hospital (ISTH) has faced these
challenges for many years. ISTH serves as a referral hospital in
Edo State, one of the many Nigerian States with evidence of Lassa
fever [1,9,12,17,32–37]. In 2001, ISTH was designated as a
Centre of Excellence in the management of Lassa fever, along with
two other federal tertiary health institutions. It set up awareness
campaigns to sensitize hospital staff and the public to the severity
of Lassa fever infection and need for treatment and prevention.
Ribavirin was periodically supplied to the hospital by the Federal
Ministry of Health and given to suspected cases. Prevalence and
case fatality figures based on clinical suspicion and pilot laboratory
investigations in 2003 and 2004 suggested a high incidence of
Lassa fever in Edo State [31], but the true magnitude of the
problem remained obscure. In 2007, the management of ISTH
was dissatisfied with the level of response and attention given to
Lassa fever and took bold steps to address the situation. Amongst
these was the establishment of the Institute of Lassa Fever
Research and Control (ILFRC). The rationale for the institute was
based on the need to build capacity to adequately respond to the
epidemics observed in the region in terms of manpower
development and training, laboratory diagnosis, and adequate
case management as well as the dire need for focused research and
advocacy. A collaborative effort was made to establish a laboratory
for molecular diagnostics of Lassa fever, which was considered
crucial for appropriate case and contact management, including
early treatment and postexposure prophylaxis with ribavirin
[23,38,39]. The diagnostic and research laboratory was built in
2008 and started operation in September 2008. We describe here
the establishment of a diagnostic service for Lassa fever and
analyze the data recorded during two years of operation.
Materials and Methods
Ethics statement
The study was classified as a service evaluation and granted
exemption from ethical review by the Research and Ethics
Committee of ISTH. Lassa fever PCR diagnostics, patient
management, and public health measures are part of routine
clinical practice at ISTH. The choice of treatment or diagnostics
was that of the clinician and patient according to professional
standards or patient preference. Neither PCR diagnostics nor
treatment with ribavirin was experimental in nature. All data
described in the manuscript stem from existing records that have
been generated as part of the regular clinical practice. The service
was evaluated 2 years after implementation. Service evaluation is
exempt from ethical review according to the National Code of
Health Research Ethics, National Health Research Ethics
Committee, Federal Ministry of Health, Nigeria.
Case definition and ribavirin treatment
The following case definition, taking into account published
signs and symptoms of Lassa fever, was used as a guideline for
Author Summary
In the past, diagnostic testing for Lassa fever patients in
Nigeria has been performed nearly exclusively outside of
the country. Patients thus were managed on-site based on
clinical suspicion alone, posing risks to patients and health
care workers and exhausting resources. To tackle this
problem, we established a diagnostic PCR laboratory
directly at a referral hospital serving a Lassa fever endemic
area in Nigeria. Long-term collaboration between partners
in the North and the South was crucial to implement this
project. Training of laboratory staff in the partner
institutions and on-site, mobilization of local human and
financial resources, good management of the laboratory, a
basic quality management and control system, and a
stable supply chain for consumables and reagents were
among the key factors for success. The laboratory reliably
delivered results in a short turnaround time, despite some
problems due to PCR contamination. The service has
improved patient and contact management including
treatment with ribavirin and led to better protection of
health care workers against hospital-acquired infections.
The data provide new insights into disease progression
and a basis for further optimization of case management
including supportive treatment.
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Lassa virus (from the diagnostic laboratory request form):
1. Patients with:
a. 38uC fever for at least 2 days
b. excluded typhoid fever and malaria negative or just 1+ in
thick smear
c. and some or one of the following symptoms: chest pain,
sore throat, headache, muscle pain, vomiting, and diarrhea.
2. Or: patients with fever who show bleeding or facial edema.
3. Or: patients with fever who do not respond to anti-malarials or
antibiotics after 2 days of treatment.
4. Or: patients with fever who had contact with a confirmed Lassa
fever case within the last three weeks.
However, as the laboratory provides routine diagnostic service
for patients, there was flexibility in applying this case definition.
Clinical experience and suspicion were taken into account as well.
In addition, in the interest of time, Lassa virus testing was often
performed before typhoid fever or malaria had been excluded.
Samples were also sent from other parts of Nigeria for Lassa virus
RT-PCR testing.
Ribavirin treatment was usually commenced on clinical grounds
before laboratory testing. If RT-PCR was negative, it was
terminated. However, in cases with a strong clinical suspicion
for Lassa fever, ribavirin treatment was continued even if the RT-
PCR was negative. If the RT-PCR was positive, treatment was
continued or commenced.
Diagnostic procedure
If a patient was suspected of having Lassa fever in any of the
clinical or outpatient departments of ISTH, staff of ILFRC
collected an EDTA blood sample. The blood was centrifuged and
virus RNA was purified from plasma by using the diatomaceous
earth method as described [40,41]. In brief, 140 ml and 14 ml,
respectively, of each plasma sample were mixed with 560 ml
chaotropic lysis buffer AVL (Qiagen) containing 5.6 mg carrier
RNA (Qiagen, no. 19073). AVL has been shown to inactivate
enveloped RNA viruses [42]. The lysate was incubated at room
temperature for 10 min. About 100 mg of diatomaceous earth
(Sigma, no. D3877) and subsequently 560 ml of ethanol was added
to the lysate and the slurry was incubated with vigorous agitation
for 10 min at room temperature in a shaker. The diatomaceous
earth was pelleted by centrifugation, and the pellet was washed
three times, first with 500 ml of buffer AW1 (Qiagen, no. 19081),
second with 500 ml of buffer AW2 (Qiagen, no. 19072), and finally
with 400 ml of acetone (each washing step included vortexing with
wash fluid, centrifugation for 2 minutes at maximum speed in a
table top centrifuge, and removal of supernatant). The pellet was
dried at 56uC for 20 minutes until the acetone was completely
evaporated. To elute the RNA from the diatomaceous earth, the
pellet was resuspended in 100 ml of water (Aqua ad injectabilia),
the slurry was vortexed, incubated 1 minute at room temperature,
centrifuged at maximum speed, and the supernatant was
transferred to a new tube. The RNA was immediately used for
PCR. The Lassa virus RT-PCR targeting the GPC gene was
performed using QIAGEN OneStep RT-PCR Kit reagents
(Qiagen, no. 210210 or 210212) as described [28]. The 25-ml
assay contained 5 ml RNA, 0.6 mM primer 36E2 (ACC GGG
GAT CCT AGG CAT TT), 0.6 mM primer LVS-339-rev (GTT
CTT TGT GCA GGA MAG GGG CAT KGT CAT), 0.4 mM
dNTP, 16RT-PCR buffer, 16Q-solution, and 1 ml enzyme mix.
The reaction was performed in a Primus25advanced thermocycler
(PeqLab, Erlangen, Germany) using the following temperature
profile: 50uC for 30 min, 95uC for 15 min, followed by 45 cycles of
95uC for 30 s, 52uC for 30 s and 72uC for 30 s. All pre-PCR
pipetting was performed with filter tips. PCR products were
separated in a 1.5% agarose gel containing ethidium bromide and
visualized by UV light. Gel images were recorded with a digital
camera. As a positive control, inactivated culture supernatant of
cells infected with Lassa virus strain CSF was used. All
consumables, reagents, chemicals, kits, and plastic materials were
purchased in Germany or the US and transferred to ISTH.
Sequencing and phylogenetic analysis
PCR products generated in the diagnostics from September
2008 through February 2011 were stored at 220uC and
sequenced retrospectively using primer 36E2. The automated
base calling was proof-read by visual inspection of the electro-
pherograms. A representative set of 35 sequences has been sent to
GenBank and assigned the accession nos. JN651366-JN651400.
Phylogenetic analysis included all novel GPC sequences (n=204)
as well as Lassa virus sequences available from GenBank by May
2011. The program jModelTest 0.1.1 [43] identified the general
time-reversible model of sequence evolution with a gamma
distribution of among-site nucleotide substitution rate variation
(GTR+gamma) as the substitution model that best describes the
data in the nucleotide sequence alignment of the partial GPC
genes (284 taxa, 237 sites). The gamma+invariant sites model was
not considered because it was not favored by jModelTest, and
because the two parameters estimated under this model (the
gamma distribution shape parameter and the proportion of
invariant sites) are highly correlated and may be poorly estimated
depending on the number of taxa [44]. Phylogenies were inferred
by the Bayesian Markov Chain Monte Carlo method implement-
ed in BEAST software [45] using the following parameters:
GTR+gamma; 10
7 steps with sampling every 10
5th step; and two
independent runs combined (effective sampling size .100 for all
parameters). To avoid over-parameterization – considering that
the sequences were short – simple molecular clock and
demographic models were chosen, that is strict clock with mean
substitution rate fixed at 1 and constant population size.
Data management and statistical analysis
Demographic data as well as major symptoms at presentation
were recorded on the request form that accompanied the blood
sample. The department responsible for the patient provided
clinical chemistry data generated in the Clinical Pathology
Department of ISTH and data on treatment and outcome. Data
were entered into a database (Excel, Microsoft) maintained at
ILFRC. All patients from whom samples were processed in the
Lassa fever diagnostics laboratory from January 2009 through
December 2010 were included in the analysis. Each case was
included only once; further testings on the same case were not
considered. The data set was checked using plausibility criteria. A
PCR result was corrected before analysis if the sequence of the
PCR product indicated a false positive result, e.g. if the sequence
corresponded to that of the positive control. Statistical comparison
of unpaired groups was performed for continuous parameters with
the Mann-Whitney test and for frequencies with two-tailed
Fisher’s Exact test. A critical p value of 0.01 was considered
appropriate, given the large number of tests performed on the data
set. The p value was further lowered to 0.001–0.0005 according to
Bonferroni correction if multiple tests were conducted within one
category (e.g. within the category profession).
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Establishment of a laboratory for molecular diagnosis of
Lassa fever
The laboratory was built in 2008 on the campus of ISTH.
Equipment was provided by Bernhard-Nocht-Institute for Trop-
ical Medicine (BNI), Harvard University, and University of Ibadan
after initiating collaborations with the hospital in 2007. These
partners also performed on-site trainings before and regularly
during operation of the laboratory. In addition, staff of ILFRC was
trained for 3 months in PCR technology at BNI in Hamburg and
at Harvard University in Cambridge, Massachusetts. The
laboratory started operation in September 2008. It is divided into
three zones to minimize PCR contamination: a ‘‘clean’’ area for all
pre-PCR manipulations, a ‘‘grey’’ area for amplification, and a
‘‘dirty’’ area for post-PCR manipulations (Figure 1A). The clean
area features separate rooms for i) sample inactivation, ii) RNA
extraction and PCR setup, and iii) mastermix preparation. The
workflow starts with sampling blood using a closed syringe system.
The sample is processed the same day or, if it arrives late, it is
stored at 4uC and processed the next day. The syringe container is
opened within a plexiglas box in the inactivation room and the
plasma is mixed with chaotropic buffer to inactivate the virus and
prepare RNA, or aliquoted for storage at 220uC (Figure 1B).
From each plasma sample, 140 ml and 14 ml are inactivated and
processed separately. The reason for testing two different volumes
per sample is to avoid false negative results due to PCR inhibition,
which appears to be a particular problem with samples from
patients with severe hemorrhagic fever [46]. If the undiluted
sample (140 ml) would be false negative due to inhibition, the 1/
10-volume sample (14 ml) was expected to be positive due to the
dilution of the inhibitor. In addition, running two PCRs in parallel
on a patient sample enhances the reliability of the diagnostic
process, as in most Lassa fever cases both samples were positive
due to the high virus load (see below). RNA is extracted from
samples and a negative control by the diatomaceous earth method
[40] in the RNA extraction room. This method is inexpensive, and
has been demonstrated to recover RNA over a broad concentra-
tion range with high efficacy [47]. The RT-PCR mastermix is
prepared in the mastermix room and transferred to the extraction
room for setting up the reaction. The closed PCR vials are
transferred to the PCR thermocycler in the ‘‘grey’’ area. After
completion of the PCR run, the closed vials are transferred to the
detection room in the ‘‘dirty’’ area for agarose gel electrophoresis
and gel documentation. PCR results are technically evaluated and
transmitted to the clinics on a report form (Figure 1C). If either the
undiluted or the 1/10-volume sample was positive, additional tests
were performed to exclude PCR contamination. Gel pictures were
transmitted to BNI staff via the internet for process monitoring.
Standard laboratory procedures were defined in a set of quality
management documents.
Laboratory testing
During 2009 through 2010, the laboratory has processed blood
samples of 1650 patients. Testing a second sample was requested
for 57/1650 patients; all other patients were tested once.
Retrospective verification of positive test results by sequencing
the PCR products revealed that in 13/1650 cases (0.8%), the result
was probably false positive result due to PCR contamination. The
sequences of the corresponding PCR fragments matched exactly
Figure 1. Molecular testing for Lassa virus at ISTH. (A) Outline of
the diagnostic laboratory with pre- and post-PCR areas (‘‘Clean’’ and
‘‘Dirty’’, respectively). (B) Inactivation of plasma samples in a chaotropic
buffer in a plexiglas box in the inactivation room. All sample
manipulations were done behind a plexiglas shield. The box features
a UV light source on top for decontamination. (C) Example of an RT-PCR
result. From each patient sample, 140 ml and 14 ml were processed
(lanes UD [undiluted] and 1:10, respectively).
doi:10.1371/journal.pntd.0001839.g001
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Lassa virus PCR-positive
Category
All patients tested
(n=1650)
Lassa virus PCR-negative
(n=1452) All (n=198)
Survived
(n=109)
a
Died
(n=61)
b
Age (years)
Median (Q25–Q75) 28 (18–43) 28 (17–42)
* 32 (23–46)
* 30 (22–40)
# 40 (24–58)
#
N data points 1579 1384 195 108 60
Gender, n (%)
Female 809 (50) 713 (50) 96 (49) 57 (53) 27 (44)
Male 823 (50) 722 (50) 101 (51) 51 (47) 34 (56)
N data points 1632 1435 197 108 61
Profession, n (%)
Child 0–4 years 170 (12) 156 (12) 14 (8.5) 8 (8.9) 5 (10)
Child 5–9 years 103 (7.3) 95 (7.6) 8 (4.8) 4 (4.4) 2 (4.0)
Child 10–15 years 72 (5.1) 65 (5.2) 7 (4.2) 3 (3.3) 3 (6.1)
Student 256 (18) 224 (18) 32 (19) 24 (26) 3 (6.1)
Trader 137 (9.7) 118 (9.5) 19 (11) 10 (11) 7 (14)
Civil servant 125 (8.8) 115 (9.2) 10 (6.1) 4 (4.4) 4 (8.1)
Healthcare worker 98 (6.9) 93 (7.4) 5 (3.0) 3 (3.3) –
Farmer 98 (6.9) 80 (6.4) 18 (10) 8 (8.9) 9 (18)
Business 61 (4.3) 54 (4.3) 7 (4.2) 1 (1.1) 3 (6.1)
Workman/engineer 50 (3.5) 42 (3.3) 8 (4.8) 6 (6.7) –
Teacher/lecturer 45 (3.2) 38 (3.0) 7 (4.2) 5 (5.6) –
House wife 32 (2.2) 28 (2.2) 4 (2.4) – 4 (8.1)
Pensioner 22 (1.5) 17 (1.3) 5 (3.0) 2 (2.2) 2 (4.0)
Tailor 20 (1.4) 19 (1.5) 1 (0.6) 1 (1.1) –
Applicant 19 (1.3) 17 (1.3) 2 (1.2) 2 (2.2) –
Driver 19 (1.3) 17 (1.3) 2 (1.2) 1 (1.1) –
Office/academics 18 (1.2) 14 (1.1) 4 (2.4) 1 (1.1) 2 (4.0)
Banking 10 (0.7) 9 (0.7) 1 (0.6) 1 (1.1) –
Clergyman 10 (0.7) 5 (0.4) 5 (3.0) 1 (1.1) 4 (8.1)
Hair dresser 9 (0.6) 7 (0.5) 2 (1.2) 2 (2.2) –
Security/police 8 (0.5) 6 (0.4) 2 (1.2) 1 (1.1) 1 (2.0)
Other 24 (1.7) 23 (1.8) 1 (0.6) 1 (1.1) –
N data points 1406 1242 164 89 49
State of Origin, n (%)
Edo 1439 (89) 1268 (89) 171 (88) 94 (87) 52 (88)
Ondo 63 (3.9) 48 (3.4) 15 (7.7) 13 (12) 1 (1.6)
FCT 29 (1.8) 26 (1.8) 3 (1.5) – 2 (3.3)
Ebonyi 21 (1.3) 20 (1.4) 1 (0.5) – 1 (1.6)
Nasarawa 2 (0.1) – 2 (1.0) – 2 (3.3)
Other 49 (3.0) 48 (3.4) 1 (0.5) – 1 (1.6)
N data points 1603 1410 193 107 59
LGA of Edo, n (%)
Esan West 458 (31) 407 (32) 51 (29) 33 (35) 9 (17)
Esan Central 361 (25) 322 (25) 39 (22) 22 (23) 12 (23)
Esan North East 195 (13) 168 (13) 27 (15) 15 (15) 9 (17)
Etsako West 114 (7.9) 93 (7.3) 21 (12) 9 (9.5) 8 (15)
Owan West 59 (4.1) 49 (3.8) 10 (5.8) 5 (5.3) 5 (9.6)
Esan South East 52 (3.6) 47 (3.7) 5 (2.9) 2 (2.1) 1 (1.9)
Igueben 43 (2.9) 40 (3.1) 3 (1.7) 2 (2.1) 1 (1.9)
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sample processed before. For data analysis, these samples were re-
classified as negative, as well as samples which have initially been
reported as indeterminate (n=12; e.g. faint PCR signals that were
not confirmed in a second blood sample). Applying these criteria,
1452 cases (88%) were Lassa RT-PCR negative, and 198 cases
(12%) were positive. Undiluted and 1/10-volume RNA extract
were positive in 138 (70%) cases and one of both was positive in 60
(30%) of the Lassa fever cases. The outcome was known for 170
cases with confirmed Lassa fever: 61 died and 109 survived. Thus,
the CFR is 31% if calculated based on all Lassa fever patients or
36% if calculated based on cases with known outcome.
Demographic data of patients (Table 1)
The vast majority of the patients came from Edo State, in
particular from the Local Governmental Areas (LGA) surrounding
ISTH, namely Esan West, Esan Central, Esan North East, Etsako
West, and Owan West (Figure 2). Several patients also came from
the neighboring state of Ondo, and a few samples were sent from
other parts of Nigeria. The median age of Lassa fever patients was
32 years. Those who died from the disease were older than those
who survived (p=0.005) (Figure 3). The proportion of males and
females was equal, and no association with outcome was observed.
Children and students made up about one third of the patients.
Adult patients had various professions and no specific profession
was associated with the outcome of Lassa fever. When comparing
the demographic data of Lassa fever negative versus positive
patients, no statistically significant differences were observed with
the exception of age, which tended to be higher among the positive
patients (p=0.006).
Hospital and disease-related data (Table 2)
Patients presented at the hospital 5 days (median) after onset of
symptoms. Lassa fever positive patients presented slightly later
than those who tested negative (median difference 1.5 days,
p=0.009). A blood sample for Lassa fever diagnostics was taken
from 75% of the patients at the day of presentation or the
following day without differences among the groups. Lassa fever
patients stayed longer in hospital and had a longer duration of
illness than those who tested negative (p=0.002 and p=0.01,
respectively). Clear differences in these two categories were
observed between fatal cases of Lassa fever and survivors.
Survivors stayed 10 days in hospital and had duration of illness
of 16 days, while patients died from Lassa fever 2 days after
admission and 10 days after onset of symptoms (figures are
median; p,0.0001 and p,0.0001, respectively) (Figure 3). The
time window for therapeutic intervention was extremely short:
25% of the fatal cases died one day after admission and the same
day the blood sample was taken for Lassa virus RT-PCR; 75%
died within 4 days of hospitalization and within 3 days after
sampling for PCR.
Patients with signs of Lassa fever were seen in virtually all
clinical and outpatient departments of ISTH. The vast majority of
requests for Lassa fever testing came from the emergency
departments, the medical wards, and the outpatient departments.
Lassa fever patients were significantly more frequent among
patients attending the adult emergency department (detection rate
19%; p,0.0001) while they were underrepresented among
patients attending the outpatient departments (detection rate
5%; p,0.0001). Thus, nearly two thirds of laboratory-confirmed
Lassa fever cases were seen in the emergency departments of
ISTH.
Median axilliary body temperature recorded at the time of
presentation was 37.5uC for all patients tested. Thus, most of them
had a body temperature lower than indicated in the case definition
($38uC). Body temperature was slightly higher for those who
tested positive (p=0.003). However, patients who had a fatal
outcome had 0.8uC lower temperature (median difference) than
those who survived (p,0.0001) (Figure 3). Indeed, nearly half of
the fatal cases had normal axilliary temperature (35.5uC–37uC)
[48] and 75% had #38uC. A few had hypothermia (#35.5uC).
The CFR among Lassa fever patients was three times higher
than the fatality rate among patients who tested negative for Lassa
fever (p,0.0001), and negative patients were 10-times less
frequently admitted to hospital than positive patients
(p,0.0001). Ribavirin treatment was given to nearly all labora-
tory-confirmed Lassa fever patients, although several patients who
tested negative received the drug as well, at least initially. While all
Table 1. Cont.
Lassa virus PCR-positive
Category
All patients tested
(n=1650)
Lassa virus PCR-negative
(n=1452) All (n=198)
Survived
(n=109)
a
Died
(n=61)
b
Akoko Edo 35 (2.4) 33 (2.6) 2 (1.1) – 2 (3.8)
Owan East 27 (1.8) 24 (1.8) 3 (1.7) 1 (1.0) 2 (3.8)
Etsako Central 21 (1.4) 20 (1.5) 1 (0.5) 1 (1.0) –
Uhunmwode 19 (1.3) 12 (0.9) 7 (4.0) 3 (3.1) 2 (3.8)
Etsako East 12 (0.8) 11 (0.8) 1 (0.5) – 1 (1.9)
Egor 4 (0.2) 3 (0.2) 1 (0.5) 1 (1.0) –
Other 39 (2.7) 39 (3.0) – – –
N data points 1439 1268 171 94 52
Due to a variable number of missing values, the number (n) of data points that were included in the analysis is indicated with each category.
Abbreviations: FCT, Federal Capital Territory; LGA, Local Government Area; Q25, lower quartile, 25% of the data lie below this value; Q75, upper quartile, 75% of the data
lie below this value.
aPatients who were discharged after recovery.
bPatients who died during hospitalization.
*p,0.01 (PCR-negative vs. PCR-positive).
#p,0.01 (PCR-positive survived vs. PCR-positive died).
doi:10.1371/journal.pntd.0001839.t001
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southern part of Nigeria showing location of Edo State. Most of the
samples came from Edo State and the neighboring Ondo State. FCT,
Federal Capital Territory. Bottom: Map of Edo State with borders of the
Local Governmental Areas (LGA). LGAs with confirmed Lassa fever cases
are shaded from light to dark grey depending on the number of cases.
The names of the LGAs with case number in parentheses are given
below the map.
doi:10.1371/journal.pntd.0001839.g002
Figure 3. Box-plot representation of statistically significant
differences between survivors and fatal cases of Lassa fever.
Urea and creatinine blood levels were drawn at admission. Comparison
of unpaired groups was performed with the Mann-Whitney test. The
number of cases per group is given below the plots in parentheses.
doi:10.1371/journal.pntd.0001839.g003
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Lassa virus PCR-positive
Category
All patients tested
(n=1650)
Lassa virus PCR-
negative
(n=1452) All (n=198) Survived (n=109)
a Died (n=61)
b
Time from onset to presentation (days)
Median (Q25–Q75) 5 (2–11) 5 (2–11)
* 6.5 (4–10)
* 6 (3–10) 7 (4–10)
N data points 1273 1099 174 97 51
Time from presentation to sampling for PCR (days)
Median (Q25–Q75) 0 (0–1) 0 (0–1) 0 (0–1) 0 (0–1) 0 (0–1)
N data points 1481 1292 189 103 59
Duration of hospitalization (days)
c
Median (Q25–Q75) 6 (3–10) 5 (3–10)
* 8 (3–11)
* 10 (8–13)
## 2 (1–4)
##
N data points 860 694 166 101 57
Duration of illness (days)
d
Median (Q25–Q75) 12 (7–18) 11 (7–18)
* 15 (11–21)
* 16 (13–23)
## 10 (7–14)
##
N data points 787 628 159 98 52
Department, n (%)
Emergency Adults 518 (32) 420 (29)
** 98 (50)
** 54 (50) 32 (54)
Emergency Children 247 (15) 223 (15) 24 (12) 13 (12) 10 (16)
Medical 266 (16) 238 (16) 28 (14) 16 (14) 11 (18)
Outpatient 316 (19) 300 (21)
** 16 (8.2)
** 12 (11) 1 (1.7)
Gyn & Obstetrics 60 (3.7) 54 (3.8) 6 (3.1) 4 (3.7) –
Pediatrics 34 (2.1) 30 (2.1) 4 (2.0) 1 (0.9) –
Surgery 17 (1.0) 16 (1.1) 1 (0.5) 1 (0.9) –
Ear Nose Throat 20 (1.2) 20 (1.4) – – –
Staff/HCW 28 (1.7) 26 (1.8) 2 (1.0) 1 (0.9) –
Intensive Care 1 (0.1) 1 (0.1) – – –
Not ISTH 98 (6.1) 83 (5.8) 15 (7.7) 5 (4.6) 5 (8.4)
N data points 1605 (100) 1411 (100) 194 (100) 107 (100) 59 (100)
Axillary body temperature on presentation (uC)
e
Median (Q25–Q75) 37.5 (36.7–38.4) 37.5 (36.6–38.3)
* 37.9 (37.0–38.8)
* 38.0 (37.4–38.9)
## 37.2 (36.1–
38.0)
##
N data points 1338 1164 174 95 52
Outcome, n (%)
Death 185 (13) 124 (10)
** 61 (32)
** – 61 (100)
Referred 26 (1.9) 21 (1.7) 5 (2.6) – –
DAMA 38 (2.7) 33 (2.8) 5 (2.6) – –
Not admitted 431 (31) 425 (36)
** 6 (3.2)
** ––
Discharged 685 (50) 576 (48) 109 (58) 109 (100) –
N data points 1365 1179 186 109 61
Ribavirin, n (%)
Yes 276 (19) 107 (8.5)
** 169 (92)
** 107 (100)
## 41 (77)
##
No 1163 (81) 1149 (91) 14 (7.6) – 12 (23)
N data points 1439 1256 183 107 53
Due to a variable number of missing values, the number (n) of data points/patients that were included in the analysis is indicated with each category.
Abbreviations: DAMA, discharge against medical advice; Q25, lower quartile, 25% of the data lie below this value; Q75, upper quartile, 75% of the data lie below this
value.
aPatients who were discharged after recovery.
bPatients who died during hospitalization.
cTime from presentation to either death in hospital, DAMA, referral to another hospital, or discharge after recovery.
dTime from onset of illness to either death in hospital, DAMA, referral to another hospital, or discharge after recovery.
enormal range 35.5–37.0uC [48].
*p,0.01 (PCR-negative vs. PCR-positive).
**p,0.0001 (PCR-negative vs. PCR-positive).
##p,0.0001 (PCR-positive survived vs. PCR-positive died).
doi:10.1371/journal.pntd.0001839.t002
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outcome did not receive ribavirin because they died the day of
presentation or the next day.
Virological and clinical data for Lassa fever patients
(Table 3)
The 1/10-volume sample (defined as 2+ score) was more
frequently positive in fatal cases than in survivors (p=0.001),
indicating higher virus load in fatal cases. Clinical symptoms
reported at presentation largely matched the known symptoms of
Lassa fever [10,14–20]. The only symptom that was significantly
more frequent among fatal cases was bleeding (p=0.0001). Urea
and creatinine blood levels were available for a subset of patients.
Both values were clearly elevated in fatalities compared to
survivors (p,0.0001 for urea and creatinine) (Figure 3).
Seasonality of Lassa fever
Two levels of seasonality were observed (Figure 4). First, the
total number of tests followed a seasonal pattern. From April
through October, about 25% fewer patients were tested than in
the remaining months. Second, the percentage of Lassa fever
positive samples dropped by about 50% in the same period. Both
effects led to a seasonal pattern with high Lassa fever incidence in
the hospital from November through March (dry season) and low
incidence from April through October (rainy season).
Molecular epidemiology of Lassa virus in Edo State and
other parts of Nigeria
The short PCR fragments obtained in routine diagnostics were
sequenced and subjected to phylogenetic analysis. Sequences from
Edo and Ondo State cluster within lineage II (Figure 5). New
sequences obtained from samples sent from Adamawa State
(Nig11–205 and Nig11–208 from Yola) and Ebonyi State (Nig11–
186 from Abakaliki and Nig10–148 from Izzi) also cluster with
lineage II, while sequences of samples from Nasawara State
(Nig09–072 from Akwanga) and the Federal Capital Territory
(Nig09–121 and Nig09–193 from Abuja) cluster with lineage III.
This is in agreement with the known geographical distribution of
Lassa virus lineages in Nigeria [3,49]. In addition, one sequence
from Edo State (Nig09–045) was found to cluster with the new
putative lineage that was recently described in Edo State and is
defined by sequence Nig05-A08 (marked with ‘‘?’’ in Figure 5)
[49]. All other sequences from Edo and Ondo State form a
separate clade within lineage II that can be further subdivided into
three clusters (A, B, and C), although the posterior probability
support for cluster C is weak (Figure 6). The analysis of larger
sequences might substantiate this tree topology. Strains within
these three clusters do not show a strict geographical clustering,
presumably because the sequences are too short to further resolve
the relationships. However, there are a few visible associations
between the origin of the strains and their phylogeny. Cluster A
contains strains from Esan West and Uhunmwode, cluster B
contains mainly strains from Esan Northeast and Central, while
cluster C contains strains from all parts of Edo State as well as the
strains from Ondo State. Even though the sequences are too short
for an association study, it is worth mentioning that there is no
obvious clustering of strains from patients with fatal outcome; they
are randomly distributed over the whole phylogenetic tree.
Discussion
Pilot investigations initiated in 2003 by the University of
Lagos, ISTH, and BNI suggested that Edo State is a hot-spot for
Lassa fever [31]. These data led to the decision to establish at
ISTH a routine diagnostic service for Lassa fever to facilitate
appropriate case management. It was further decided to use
PCR as it offers case detection at an early stage [24,25]. The
training of staff members of ISTH in theory and practice of
diagnostic PCR in partner institutions and on-site has been of
paramount importance for the implementation of this technol-
ogy at ISTH. Featuring separate areas for virus inactivation,
RNA extraction, and mastermix preparation, the laboratory
complies with basic standards of diagnostic PCR facilities. To
guarantee smooth operation of the laboratory, technologies and
workflow of the diagnostic facility at BNI in Hamburg were
‘‘mirrored’’ at ISTH, with only minor modification. This
strategy facilitated training, interchangeability of protocols,
and troubleshooting.
The most recent version of the GPC gene-specific RT-PCR
assay [28] was chosen as a PCR assay and samples were tested
Table 3. Virological and clinical data for Lassa fever patients.
Lassa virus PCR-positive
Category Survived (n=109)
a Died (n=61)
b
Lassa virus load on presentation
(score)
c
1+ 29 (27)
# 4 (6.5)
#
2+ 80 (73) 57 (93)
N data points 109 61
Symptoms and signs on
presentation
Fever 100 (94) 46 (88)
Vomiting 54 (50) 18 (34)
Headache 52 (49) 20 (38)
Abdominal pain 42 (39) 16 (30)
Sore throat 18 (17) 6 (11)
Cough 16 (15) 13 (25)
Chest pain 15 (14) 5 (9.6)
Joint/body pain 14 (13) 8 (15)
Diarrhea 9 (8.4) 10 (19)
Bitter taste 5 (4.7) 2 (3.8)
Bleeding 5 (4.7)
# 14 (26)
#
Jaundice 5 (4.7) 3 (5.7)
Breathing difficulties 4 (3.7) 6 (11)
Convulsion/seizure 3 (2.8) 4 (7.6)
Facial edema 3 (2.8) 2 (3.8)
Dizziness 2 (1.8) –
Hearing problem 1 (0.9) –
Unconsciousness 1 (0.9) 2 (3.8)
Dark urine 1 (0.9) 3 (5.7)
Abortion 1 (0.9) –
N data points 106 52
Due to a variable number of missing values, the number (n) of data points that
were included in the analysis is indicated with each category.
Abbreviations:
aPatients who were discharged after recovery.
bPatients who died during hospitalization.
c1+, Lassa virus RT-PCR was only positive with undiluted plasma; 2+, Lassa virus
RT-PCR was positive with 1/10-volume plasma, irrespective of whether the
undiluted sample was positive or not.
#p,0.01 (PCR-positive survived vs. PCR-positive died).
doi:10.1371/journal.pntd.0001839.t003
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minimize the problem of PCR inhibition [46]. Indeed, several
samples tested positive with the 1/10-volume RNA preparation
only and contamination was excluded in most of them by
sequencing. It is likely that in these cases amplification of the
undiluted sample was inhibited. A modification to the BNI
procedures has been the use of diatomaceous earth for RNA
preparation instead of a commercial kit to reduce the costs
[40].
The main problem that arose during operation of the laboratory
was PCR contamination, which was confirmed by sequencing of
the PCR products. It was probably facilitated by the high
analytical sensitivity of the assay (15 virus genome copies per
reaction are detected with a likelihood of 95%) [28] and the need
to open the reaction tubes for detection in agarose gel. The staff of
the laboratory was aware of this inherent problem of PCR and
protocols were developed to minimize and cope with it. We found
retrospective evidence for reporting a false positive result in about
1% of the cases tested, which corresponds to an analytical
specificity for the whole diagnostic process of 99% and an overall
positive predictive value of 90%. However, with one exception, all
contaminations manifested in only one of the two reactions
(undiluted and 1/10-volume) performed on each sample. Thus,
the positive predictive value for the majority of positive samples,
namely those positive in both reactions is 99%, while the positive
predictive value for samples positive in only one of the two
reactions is 80%. Overall, we consider these good performance
characteristics for a PCR diagnostics performed in a resource-
limited setting.
Complementing the RT-PCR by antibody testing would further
improve the reliability of the diagnostics. On the one hand,
serology may be used to confirm the PCR diagnosis in patients
who have already developed antibodies during the acute phase.
On the other hand, antibody testing facilitates detection of patients
Figure 4. Seasonality of Lassa fever. (A) Number of cases tested, number of positive cases, and percentage of positive cases per month. (B)
Average of incidence figures. The curves in A were smoothened by a sliding window covering a 3-month interval and subsequent averaging of the
two years. Error bars indicate the range. The rainfall in Benin City is shown as a bar chart in the background in relative units (July=360 mm). Climate
data were taken from http://www.climatedata.eu/climate.php?loc=nizz0004&lang=en (accessed 1 June 2012).
doi:10.1371/journal.pntd.0001839.g004
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the detection limit of the PCR [25,26,50].
The demographic data of the patients did not provide clues as to
risk factors associated with Lassa fever; profession, geographic
origin, and gender did not differ significantly between patients who
tested positive and those who tested negative. However, a seasonal
pattern of Lassa fever incidence was observed with the lowest
number of cases during April through October, which corresponds
to the rainy season. Similar, though not identical seasonal
fluctuations have been described in Sierra Leone and Guinea
[14,15,51]. The reason for a decrease in incidence during rainy
season is not clear. Behavioral changes may play a role, as the
number of all patients tested also decreased during this time, which
may suggest that patients attend the hospital less frequently in
rainy than in dry season. In addition, rodent dynamics and climate
factors influencing the efficacy of virus transmission from the
reservoir to humans may be involved [2,52].
The CFR of 31% is high, though in the range of previous
reports. In hospitalized patients with endemic Lassa fever, the
CFR ranged from 9.3% to 18% [14–16,51,53,54]. During
nosocomial outbreaks, the CFR appears to be higher, ranging
from 36% to 65% [9–12]. However, these figures are not fully
comparable, due to differences in case definitions and diagnostic
methods used in the various studies. Half of the patients with
febrile illness attended ISTH at day 5 after onset of symptoms or
later, and 50% of those with Lassa fever even at day 6 or later. The
efficacy of ribavirin treatment decreases with progression of the
disease and is hardly effective after day 6 [23]. Thus, a large
number of Lassa fever patients attending ISTH did not benefit as
greatly as they could have from the administration of ribavirin
early in their disease course. This may explain the CFR of one
third. Indeed, the time for therapeutic intervention is extremely
short, as 50% of the fatal cases die before day 10 of illness and
within 2 days in hospital—often before ribavirin treatment could
be commenced. The severity of Lassa fever also explains why most
of the patients attend the emergency department rather than the
general outpatient departments.
A few parameters were identified which differ significantly
between fatal cases of Lassa fever and survivors and are not yet
documented in the literature. An important finding was lower body
temperature in fatal cases. Often the temperature was not elevated
at all or even below thenormalrange (,35.5uC).This resemblesthe
sepsis-associated hypothermia which is a predictor of poor outcome
[55,56]. Although hypothermia is common in end-stage shock and
organ failure of any etiology and not specific for Lassa fever, this
sign has implications for the case definition of Lassa ‘‘fever’’, which
apparently needs to be revised to facilitate sensitive detection of
cases in the terminal stage. Another factor associated with fatal
outcome was higher age. Elderly people are also at higher risk of
dying from sepsis, which is thought to be related to a reduced
immune status or immune dysfunction [57,58]. Bleeding was
identified as the only clinical sign at presentation associated with
poor outcome. Creatinine and blood urea levels were strongly
elevated in the fatal cases suggesting renal failure. The semiquan-
titative PCR data also indicated higher virus load in patients with
poor prognosis, which is consistent with published data [26].
Figure 5. Phylogenetic analysis of Lassa virus sequences. The sequences of the PCR fragments obtained from positive cases were aligned with
published sequences. The latter are identified by GenBank accession numbers. For clarity of presentation, only Nigerian strains are shown. The
clusters A, B, and C comprising strains from Edo State and Ondo State were collapsed; these strains are shown separately in Figure 6. Posterior
probability values are indicated on the branches. The country of origin of Lassa virus strains is indicated by a prefix: IC, Ivory Coast; NIG, Nigeria. If
known, State and city is also shown with the strains (FCT, Federal Capital Territory). Sequences highlighted in boldface have been submitted to
GenBank (accession nos. JN651366-JN651400). Lassa virus lineages are indicated left. The novel putative lineage/sub-lineage represented by strain
Nig05-A08 [49] is indicated with a question mark.
doi:10.1371/journal.pntd.0001839.g005
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PLOS Neglected Tropical Diseases | www.plosntds.org 12 September 2012 | Volume 6 | Issue 9 | e1839The burden of Lassa fever in most regions of Nigeria is not
known, as hospitals are not able to detect Lassa fever patients by
laboratory testing. In future, surveillance systems including
laboratory confirmation in reference centers need to be imple-
mented in the country. Taken together, the data from ISTH
indicate that fatal cases of Lassa fever are characterized by the
following criteria:
N Presentation within 10 days after onset of symptoms.
N History of fever and/or fever at presentation.
N Attendance of the emergency department.
N Severe systemic disease including renal failure and/or normo-
or hypothermia.
N Symptoms include vomiting, diarrhea, abdominal pain,
headache, cough, or bleeding.
N Fatal outcome within four days after hospital admission despite
antimalaria and antibiotic treatment.
We propose to use the above set of criteria as a surveillance tool
to identify hospitals that are attended by Lassa fever patients.
While this case definition is less sensitive, as it targets fatal cases
only (‘‘the tip of the iceberg’’), it may be more specific for Lassa
fever than existing ones.
The sequences generated from the short PCR products
confirmed previous studies showing that Lassa virus strains from
Edo State cluster phylogenetically with lineage II [3,49]. Although
the sequences originate from the same geographical area, they are
quite diverse, which is in agreement with previous reports [3,6]. A
first attempt to correlate Lassa virus sequences with outcome did
not reveal associations at least on the level of the clades that were
resolved by the phylogenetic program. More sophisticated studies
are warranted to look into possible links between virus genetics
and clinical presentation.
In conclusion, routine diagnostics for Lassa fever has been
established at ISTH. There are two major advantages for case
management. First, early detection of a Lassa fever case improves
protection of staff from nosocomial Lassa virus transmission. In the
pre-diagnostic era, an unrecognized Lassa fever patient may have
been cared for on a regular ward for several days, before clinical
signs raised the suspicion of Lassa fever and appropriate measures
were taken. Now, Lassa fever cases are transferred immediately to
a specific ward where they are appropriately managed. In
addition, close contacts to the Lassa fever patients, including
hospital staff, can be monitored or offered ribavirin post-exposure
prophylaxis as early as possible if the contact was very close [39].
Second, ribavirin treatment can be commenced early in all Lassa
fever cases or may be terminated in non-cases if it had been
provisionally commenced on clinical suspicion. Treatment is no
longer based on clinical criteria, which is neither sensitive nor
specific. However, rapid on-site diagnosis alone probably does not
reduce the case fatality rate as long as most Lassa fever patients
present too late for ribavirin treatment to be efficacious.
The open PCR platform may be used also for molecular testing
for other pathogens. In addition, it provides the basis for research
involving the Lassa fever patient and the optimization of the
supportive treatment, including renal dialysis and intensive care.
Steps to upgrade the laboratory with equipment for viral load
determination, serology, blood chemistry, and hematology have
been undertaken.
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